Journal article
A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy.
- Jiménez VA Interventional Cardiology Unit, Cardiology Department, Hospital Alvaro Cunqueiro, University Hospital of Vigo, Vigo, Spain. Electronic address: victor.alfonso.jimenez.diaz@sergas.es.
- Iñiguez A Interventional Cardiology Unit, Cardiology Department, Hospital Alvaro Cunqueiro, University Hospital of Vigo, Vigo, Spain.
- Baz JA Interventional Cardiology Unit, Cardiology Department, Hospital Alvaro Cunqueiro, University Hospital of Vigo, Vigo, Spain.
- Valdés M Hospital Universitario V. Arrixaca, Murcia, Spain.
- Ortiz A Interventional Cardiology Unit, Cardiology Department, Hospital Alvaro Cunqueiro, University Hospital of Vigo, Vigo, Spain.
- Vuilliomenet A Kantonsspital Aarau, Aarau, Switzerland.
- Mainar V Department of Cardiology, University General Hospital of Alicante, Alicante, Spain.
- Dudek D Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland.
- Banai S Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel.
- Tüller D Department of Cardiology, Stadtspital Triemli, Zürich, Switzerland.
- Bonnet JL Department of Cardiology, Hospital La Timone, Marseille, France.
- De Miguel A Interventional Cardiology Unit, Cardiology Department, Hospital Alvaro Cunqueiro, University Hospital of Vigo, Vigo, Spain.
- Bastos G Interventional Cardiology Unit, Cardiology Department, Hospital Alvaro Cunqueiro, University Hospital of Vigo, Vigo, Spain.
- Wijns W Cardiovascular Center Aalst, OLV Hospital, Aalst, Belgium.
- Saito S Department of Cardiology and Catheterization Laboratory, Shonan Kamakura General Hospital, Kamakura, Japan.
- 2016-05-09
Published in:
- Cardiovascular revascularization medicine : including molecular interventions. - 2016
Acute coronary syndrome
bioresorbable polymer
drug-eluting stent
Absorbable Implants
Acute Coronary Syndrome
Aged
Cardiovascular Agents
Coronary Angiography
Coronary Restenosis
Drug-Eluting Stents
Europe
Everolimus
Female
Humans
Japan
Kaplan-Meier Estimate
Male
Middle Aged
Non-ST Elevated Myocardial Infarction
Percutaneous Coronary Intervention
Polymers
Prospective Studies
Prosthesis Design
Recurrence
Republic of Korea
Risk Factors
ST Elevation Myocardial Infarction
Single-Blind Method
Thrombosis
Time Factors
Treatment Outcome
English
BACKGROUND
To investigate clinical outcomes of percutaneous coronary intervention using a sirolimus-eluting stent with bioresorbable polymer, Ultimaster (BP-SES) compared with a permanent polymer everolimus-eluting stent, Xience (PP-EES) in patients with high risk (ST-segment elevation and non-ST-segment elevation myocardial infarction) acute coronary syndromes (ACS) enrolled in the CENTURY II trial.
METHODS
CENTURY II is a prospective, multicenter, randomized, single blind, controlled trial comparing BP-SES and PP-EES, with primary endpoint of target lesion failure (TLF) at 9month post-stent implantation. Out of 1123 patients enrolled in CENTURY II trial, 264 high risk ACS patients were included in this subgroup analysis, and the clinical outcomes including target lesion failure (TLF), target vessel failure (TVF), cardiac death, myocardial infarction, and stent thrombosis were evaluated at 24months.
RESULTS
The baseline clinical, angiographic and procedural characteristics were similar between two groups. At 24months, TLF occurred in 6.3% of patients receiving a BP-SES and 6.5% of patients receiving a PP-EES (P=0.95); TVF was 6.3% in patients receiving a BP-SES and 9.4% in patients receiving a PP-EES (P=0.36). There were no significant differences in cardiac death, myocardial infarction and stent thrombosis rate.
CONCLUSIONS
BP-SES achieved similar safety and efficacy outcomes as PP-EES in this ACS subgroup of CENTURY II study, at 24-month follow-up. This finding is hypothesis-generating and needs to be confirmed in larger trials with longer follow-up.
To investigate clinical outcomes of percutaneous coronary intervention using a sirolimus-eluting stent with bioresorbable polymer, Ultimaster (BP-SES) compared with a permanent polymer everolimus-eluting stent, Xience (PP-EES) in patients with high risk (ST-segment elevation and non-ST-segment elevation myocardial infarction) acute coronary syndromes (ACS) enrolled in the CENTURY II trial.
METHODS
CENTURY II is a prospective, multicenter, randomized, single blind, controlled trial comparing BP-SES and PP-EES, with primary endpoint of target lesion failure (TLF) at 9month post-stent implantation. Out of 1123 patients enrolled in CENTURY II trial, 264 high risk ACS patients were included in this subgroup analysis, and the clinical outcomes including target lesion failure (TLF), target vessel failure (TVF), cardiac death, myocardial infarction, and stent thrombosis were evaluated at 24months.
RESULTS
The baseline clinical, angiographic and procedural characteristics were similar between two groups. At 24months, TLF occurred in 6.3% of patients receiving a BP-SES and 6.5% of patients receiving a PP-EES (P=0.95); TVF was 6.3% in patients receiving a BP-SES and 9.4% in patients receiving a PP-EES (P=0.36). There were no significant differences in cardiac death, myocardial infarction and stent thrombosis rate.
CONCLUSIONS
BP-SES achieved similar safety and efficacy outcomes as PP-EES in this ACS subgroup of CENTURY II study, at 24-month follow-up. This finding is hypothesis-generating and needs to be confirmed in larger trials with longer follow-up.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1016/j.carrev.2016.04.001
- PMID 27156201
- Persistent URL
- https://sonar.ch/global/documents/186300
Statistics
Document views: 24
File downloads: